MeiraGTx Holdings PLC MGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.57
- Day Range
- $8.94–9.69
- 52-Week Range
- $5.47–11.85
- Bid/Ask
- $8.40 / $11.25
- Shares Outstanding
- 92.61M
- Market Cap
- $833.49M
- Volume/Avg
- 693,693 / 807,850
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 9.14
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 409
- Website
- https://www.meiragtx.com
Valuation
|
Metric
|
MGTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 9.14 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MGTX
|
|---|---|
Quick Ratio | 0.51 |
Current Ratio | 0.55 |
Interest Coverage | −9.13 |
Quick Ratio
MGTX
Profitability
|
Metric
|
MGTX
|
|---|---|
Return on Assets (Normalized) | −43.02% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −117.28% |
Return on Assets
MGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mnxvhll | Hpdnk | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tbsyfmnl | Qmddcz | $67B | |||
| argenx SE ADR
ARGX
| Chvzzykv | Jkk | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fxtqgdwks | Rzkyly | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Cqdzhppv | Fllkdzr | $25B | |||
| BioNTech SE ADR
BNTX
| Dwdqqyld | Zvmv | $22B | |||
| Incyte Corp
INCY
| Zwvxnsn | Dmf | $20B | |||
| Moderna Inc
MRNA
| Chbtrxj | Ckckl | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Ykdrmns | Cwtp | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Vzkldknn | Rrgp | $13B |
United States